(Q40037876)

English

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

scientific article published on December 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

1 reference

based on heuristic

inferred from title

Scott H Olejniczak

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Raymond I Cruz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Francisco J Hernandez-Ilizaliturri

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

George Deeb

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Joy Knight

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Paul Wallace

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Beth L Thurberg

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

William Kennedy

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Myron S Czuczman

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

48

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2424-2436

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

A cholesterol-dependent CD20 epitope detected by the FMC7 antibody

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Complement-regulatory proteins in ovarian malignancies

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Protection of thyroid cancer cells by complement-regulatory factors

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

The CD52 antigen and development of the CAMPATH antibodies

1 reference

https://api.crossref.org/works/10.1080%2F10428190701647879

21 January 2018

Identifiers

10.1080/10428190701647879

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18067019%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40037876&oldid=1561112409"